Analysis of human tau in cerebrospinal fluid.

No abstract is available for this paper.

• Publication year

  2010

• Venue

  Journal of Proteome Research

• Publication date

  2010-02-03

• Fields of study

  Biology, Medicine, Chemistry

• Identifiers
  DOI 10.1021/pr901002tPMID 20067323
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Cerebrospinal fluid {beta}-amyloid 42 and tau proteins as biomarkers of Alzheimer-type pathologic changes in the brain.

  2009cited by this paper
• Epitope mapping of mAbs AT8 and Tau5 directed against hyperphosphorylated regions of the human tau protein.

  2007cited by this paper
• Silver and gold nanoparticle-coated membranes for femtomole detection of small proteins and peptides by Dot and Western blot.

  2007cited by this paper
• Purification of bovine Tau versions by affinity chromatography.

  2006cited by this paper
• Characterization of bovine tau-preparations by two-dimensional gel electrophoresis.

  2006cited by this paper
• Neighbored phosphorylation sites as PHF-tau specific markers in Alzheimer's disease.

  2006cited by this paper
• Proteomics analysis of prefractionated human lumbar cerebrospinal fluid

  2005cited by this paper
• Protein Analysis in Human Cerebrospinal Fluid: Physiological Aspects, Current Progress and Future Challenges

  2005cited by this paper
• Depletion of multiple high‐abundance proteins improves protein profiling capacities of human serum and plasma

  2005cited by this paper
• Core biological marker candidates of Alzheimer’s disease – perspectives for diagnosis, prediction of outcome and reflection of biological activity

  2004cited by this paper
• CSF markers for incipient Alzheimer's disease.

  2003cited by this paper
• Advances in the development of biomarkers for Alzheimer's disease: from CSF total tau and Abeta(1-42) proteins to phosphorylated tau protein.

  2003cited by this paper
• The Human Plasma Proteome

  2002cited by this paper
• Cerebrospinal fluid analysis: disease-related data patterns and evaluation programs.

  2001cited by this paper
• Analysis of the molecular heterogeneity of the microtubule-associated protein tau by two-dimensional electrophoresis and RT-PCR.

  2000cited by this paper
• Levels of alpha- and beta-secretase cleaved amyloid precursor protein in the cerebrospinal fluid of Alzheimer's disease patients.

  2000cited by this paper
• Cerebrospinal fluid tau protein as a biochemical marker for Alzheimer’s disease: a community based follow up study

  1998cited by this paper
• Elevation of microtubule-associated protein tau in the cerebrospinal fluid of patients with Alzheimer's disease

  1995cited by this paper
• Tau protein in cerebrospinal fluid: a biochemical marker for axonal degeneration in Alzheimer disease?

  1995cited by this paper
• Detection of tau proteins in normal and Alzheimer's disease cerebrospinal fluid with a sensitive sandwich enzyme-linked immunosorbent assay.

  1993cited by this paper
• Cloning of a big tau microtubule-associated protein characteristic of the peripheral nervous system.

  1992cited by this paper
• Brain Levels of Microtubule‐Associated Protein τ Are Elevated in Alzheimer's Disease: A Radioimmuno‐Slot‐Blot Assay for Nanograms of the Protein

  1992cited by this paper
• Primary structure of high molecular weight tau present in the peripheral nervous system.

  1992cited by this paper
• Soluble derivatives of the beta amyloid protein precursor in cerebrospinal fluid: alterations in normal aging and in Alzheimer's disease.

  1990cited by this paper
• Multiple isoforms of human microtubule-associated protein tau: sequences and localization in neurofibrillary tangles of Alzheimer's disease.

  1989cited by this paper
• Proteolysis of tau by calpain.

  1989cited by this paper
• A4 amyloid protein deposition and the diagnosis of Alzheimer's disease

  1988cited by this paper
• Alzheimer‐related neuronal protein A68: Specificity and distribution

  1987cited by this paper
• Which of the commonly used marker enzymes gives the best results in colorimetric and fluorimetric enzyme immunoassays: horseradish peroxidase, alkaline phosphatase or beta-galactosidase?

  1985cited by this paper
• Clinical diagnosis of Alzheimer's disease

  1984cited by this paper
• Phosphorylation affects the ability of tau protein to promote microtubule assembly.

  1984cited by this paper
• Physical and chemical properties of purified tau factor and the role of tau in microtubule assembly.

  1977cited by this paper
• PEROXIDASE-LABELED ANTIBODY A NEW METHOD OF CONJUGATION

  1974cited by this paper
• Cleavage of Structural Proteins during the Assembly of the Head of Bacteriophage T4

  1970cited by this paper

• Promoting Secretion of Pathological Tau Species Using an Induced Proximity Platform That Engages the Autophagy Pathway.

  2025cites this paper
• Molecular and cellular mechanisms underlying the pathogenesis of Alzheimer’s disease

  2020cites this paper
• From the prion-like propagation hypothesis to therapeutic strategies of anti-tau immunotherapy

  2019cites this paper
• Tau Proteolysis in the Pathogenesis of Tauopathies: Neurotoxic Fragments and Novel Biomarkers

  2018cites this paper
• Association of Cerebrospinal Fluid Tau Protein in Patients with Alzheimer’s and Non Alzheimer’s Dementias in a Tertiary Level Hospital in Bangladesh

  2017cites this paper
• Immunological memory to hyperphosphorylated tau in asymptomatic individuals

  2017cites this paper
• De la cellule au primate, propagation physiopathologique de la protéine Tau

  2015cites this paper
• Cerebrospinal Fluid Levels of a 20–22 kDa NH2 Fragment of Human Tau Provide a Novel Neuronal Injury Biomarker in Alzheimer's Disease and Other Dementias

  2014cites this paper
• Ectosomes: A New Mechanism for Non-Exosomal Secretion of Tau Protein

  2014cites this paper
• Post-Translational Modifications in Alzheimer's Disease and the Potential for New Biomarkers

  2014cites this paper
• Melanocortins protect against progression of Alzheimer's disease in triple-transgenic mice by targeting multiple pathophysiological pathways.

  2014cites this paper
• Divergent CSF τ alterations in two common tauopathies: Alzheimer's disease and progressive supranuclear palsy

  2014cites this paper
• Characterization of Novel CSF Tau and ptau Biomarkers for Alzheimer’s Disease

  2013cites this paper
• Hydrogen sulfide slows down progression of experimental Alzheimer's disease by targeting multiple pathophysiological mechanisms.

  2013cites this paper
• Alzheimer's Disease-Related Lesions

  2012cites this paper
• Ion mobility separation of isomeric phosphopeptides from a protein with variant modification of adjacent residues.

  2011cites this paper
• Advances in proximal fluid proteomics for disease biomarker discovery.

  2010cites this paper
• Separation of multiphosphorylated peptide isomers by hydrophilic interaction chromatography on an aminopropyl phase.

  2010cites this paper
• Tau pathology: predictive diagnostics, targeted preventive and personalized medicine and application of advanced research in medical practice

  2010cites this paper